Pleuromutilins Suppress Hepatocellular Carcinoma Growth via ABCA1 Inhibition-Induced Cholesterol Accumulation
Cancers · 24.03.2026 · 18 (7) · 1054
DOI: 10.3390/cancers18071054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.03.2026. Verfasst von Mingshan Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the State Key Laboratory of Systems Medicine for Cancer, National Natural Science Foundation of China.
Abstract (Originalsprache)
Bcakground: Hepatocellular carcinoma (HCC) is a prevalent malignancy with limited therapeutic options. Drug repurposing offers an attractive strategy to accelerate anticancer discovery. The pleuromutilin class of antibiotics, including the human-approved agent lefamulin and the veterinary drug tiamulin, has shown preliminary anticancer potential, but its efficacy and mechanism in HCC remain unexplored.
Methods
The anti-tumor effects of lefamulin and tiamulin were evaluated in HCC cell lines, patient-derived organoids, and a C57BL/6 mouse subcutaneous tumor model. Safety was assessed in a human normal hepatocyte cell line and by histopathological examination of major organs in treated mice. Mechanistic investigations were performed using RNA-sequencing, RT-qPCR, immunohistochemistry (IHC), filipin staining, pharmacological rescue assays, and shRNA-mediated gene silencing.
Results
In this study, we found that both lefamulin and tiamulin markedly inhibited HCC cell proliferation in vitro and significantly suppressed tumor growth in vivo (lefamulin vs. control, p = 0.014; tiamulin vs. control, p = 0.021), without causing significant toxicity. RNA-sequencing analysis revealed consistent downregulation of the cholesterol transporter Abca1 (ATP-binding cassette transporter A1) and alterations in cell adhesion molecule pathways. Functional studies confirmed that treatment reduced ABCA1 protein levels, leading to intracellular cholesterol accumulation and aberrant distribution. Furthermore, treated tumors exhibited a significant increase in CD8+ T-cell infiltration, with CD4+ T cells and macrophage infiltration remained unchanged, indicating a specific modulation of the tumor immune microenvironment.
Conclusions
These findings suggest that lefamulin and tiamulin are promising therapeutic candidates for HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China.
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai 200127, China.
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
ORCID-Profile: Mingshan Zhou
Förderung
- the National Natural Science Foundation of China
- the State Key Laboratory of Systems Medicine for Cancer
- National Natural Science Foundation of China
- State Key Laboratory of Systems Medicine for Cancer
Zitieren
APA
Zhou, M., Cao, J., Chen, J., Zhang, B., Wu, J., Lian, X., Zhu, M., Liu, P., & Zhou, M. (2026). Pleuromutilins Suppress Hepatocellular Carcinoma Growth via ABCA1 Inhibition-Induced Cholesterol Accumulation. Cancers, 18(7), 1054. https://doi.org/10.3390/cancers18071054
Vancouver
Zhou M, Cao J, Chen J, Zhang B, Wu J, Lian X, et al. Pleuromutilins Suppress Hepatocellular Carcinoma Growth via ABCA1 Inhibition-Induced Cholesterol Accumulation. Cancers. 2026;18(7):1054. doi:10.3390/cancers18071054
BibTeX
@article{Zhou2026,
author = {Zhou, Mingshan and Cao, Jie and Chen, Junfei and Zhang, Bohan and Wu, Jiawen and Lian, Xiaofeng and Zhu, Miaoxin and Liu, Peifeng and Zhou, Min},
title = {Pleuromutilins Suppress Hepatocellular Carcinoma Growth via ABCA1 Inhibition-Induced Cholesterol Accumulation},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1054},
doi = {10.3390/cancers18071054}
}
EUVIMED